Overview
EudraVigilance (EV) is the EU’s system for managing and analysing information on
adverse reactions to medicines which have been authorised or are being studied in
clinical trials in the European Economic Area (EEA). The use of the ISO Individual
Case Safety Report (ICSR) standard based on the ICH E2B (R3) modalities became
mandatory on 30 June 2022.
For this training course, participants need an active EMA account for the practical
exercises in the EVWEB test environment (XCOMP). Participants are required to
have a good command of the English language and be proficient in using a
computer and Zoom to participate effectively in the course.
Participants are also expected to work in pharmacovigilance or SUSAR
submissions for clinical trials and to have basic background knowledge of:
The ICH pharmacovigilance guidelines;
The EU pharmacovigilance legislation;
MedDRA coding;
GVP Module VI – Management and reporting of adverse reactions to medicinal
products;
Regulation (EU) No 536/2014 on clinical trials on medicinal products for human
use;
GVP Module IX – Signal management and revised guidance on statistical
methods.
Following the completion of this course, participants who pass the knowledge
evaluation will receive a notification from the EMA. Organisations which aim to
register first user QPPV/RP or to use EudraVigilance web application (EVWEB) to
start the electronic reporting of ICSRs to EudraVigilance for the first time, need to
provide such notification for at least one user to the EMA to be able to successfully
register with the EV production environment. For more information on the
registration process, please consult the EMA website.
Have an account?